IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2025
0mins
Source: Globenewswire
Phase 3 OVATION 3 Study Initiation: IMUNON, Inc. has initiated the first trial site for its Phase 3 OVATION 3 study of IMNN-001, a DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer, following promising results from the Phase 2 OVATION 2 study that demonstrated improved survival rates when combined with chemotherapy.
Financial Results and Future Plans: The company reported a net loss of $4.1 million for Q1 2025, a decrease from the previous year, while also announcing plans to present new data at the upcoming ASCO Annual Meeting and seeking partnerships for further development of its vaccine technology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
